glp-1 dual agonist Evaluation of biased agonism mediated by agonists of the and glucagon receptors Comparing GLP-type therapies for weight

European survey finds over three-quarters of adults with obesity have attempted to lose weight in the past year, but most have been unsuccessful

Distribution and Metabolism Orforglipron exhibits distribution characteristics typical of lipophilic small molecules with moderate plasma protein binding

What should patients tell their clinicians

After setbacks in internal oral GLP-1 development, Pfizer moved to strengthen its position through acquisition activity, including its move for Metsera and its next-generation obesity portfolio

Then we had Herman Pontzer on and we talked about metabolic adaptation from the burn side, right the reason you can't marathon your way to weight loss because your body's just going to adjust